title: Effects of repeated amphetamine treatment on regional GABAA receptor binding.
abstract: The present study examined the effects of repeated exposure to amphetamine on GABAA receptor binding in cortical and subcortical areas. The goal of the study was to determine whether changes in specific binding were related to behavioral sensitization. Animals were exposed to either saline (0.3 ml, s.c.; n=12) or d-amphetamine (2.5 mg/kg, s.c.; n=12) for 6 consecutive days and sacrificed after a 14-day withdrawal period. Differences in GABAA receptor binding in these two groups of animals were assessed using the GABAA receptor antagonist [3H]SR 95531. To verify that the preceding treatment regimen led to the development of behavioral sensitization, a separate set of animals (n=8/group) was exposed to the same regimen and challenged with d-amphetamine (2.5 mg/kg, s.c.) after the 14-day withdrawal period. As expected, preexposure to amphetamine led to the development of amphetamine sensitization. There were no differences in GABAA receptor binding in animals preexposed to saline and amphetamine in the prefrontal cortex, caudate-putamen, hypothalamus, or cerebellum. These findings do not provide support for the idea that changes in GABAA receptor binding in the medial prefrontal cortex or various subcortical areas are related to the development of behavioral sensitization.
authors.affiliation: Department of Psychiatry, Millhauser Laboratories, New York University Medical Center, 550 First Ave. HN 507, New York, NY 10016, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Gruen
authors.forename: S
authors.initials: S
authors.lastname: Stoker
authors.forename: A J
authors.initials: AJ
authors.lastname: Friedhoff
authors.forename: C W
authors.initials: CW
authors.lastname: Bradberry
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology*; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D002531:Cerebellum / Q000737:chemistry; D018756:GABA Antagonists / Q000494:pharmacology; D007031:Hypothalamus / Q000737:chemistry; D008124:Locomotion / Q000502:physiology; D008297:Male; D017072:Neostriatum / Q000737:chemistry; D017397:Prefrontal Cortex / Q000737:chemistry; D011724:Pyridazines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000378:metabolism / Q000502:physiology*; D014316:Tritium
chemical_list: D018663:Adrenergic Agents; D018756:GABA Antagonists; D011724:Pyridazines; D011963:Receptors, GABA-A; D014316:Tritium; C049853:gabazine; D000661:Amphetamine